Nanotechnology Stocks To Keep An Eye On – February 22nd

OSI Systems, NVE, Virpax Pharmaceuticals, Clene, and Biodexa Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSI Systems stock traded down $12.10 during trading on Friday, hitting $202.27. 267,063 shares of the company were exchanged, compared to its average volume of 200,800. The firm has a market capitalization of $3.40 billion, a P/E ratio of 26.03, a price-to-earnings-growth ratio of 1.81 and a beta of 1.19. OSI Systems has a 1-year low of $126.57 and a 1-year high of $220.00. The firm’s fifty day moving average price is $183.86 and its 200 day moving average price is $161.79. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NVE stock traded down $2.46 during trading on Friday, hitting $73.82. 30,928 shares of the company were exchanged, compared to its average volume of 25,192. NVE has a 1-year low of $67.35 and a 1-year high of $90.24. The firm has a market capitalization of $357.29 million, a P/E ratio of 23.81 and a beta of 1.11. The firm’s fifty day moving average price is $77.33 and its 200 day moving average price is $78.15.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ:VRPX traded down $0.03 during trading hours on Friday, hitting $0.26. The stock had a trading volume of 1,803,908 shares, compared to its average volume of 8,691,735. Virpax Pharmaceuticals has a one year low of $0.23 and a one year high of $5.48. The business’s 50 day moving average is $0.33 and its 200-day moving average is $0.56.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Clene stock traded down $0.08 during mid-day trading on Friday, hitting $4.43. 51,888 shares of the company’s stock were exchanged, compared to its average volume of 44,970. The firm has a market capitalization of $36.90 million, a P/E ratio of -0.84 and a beta of 0.24. Clene has a fifty-two week low of $3.82 and a fifty-two week high of $10.40. The company’s 50 day simple moving average is $4.82 and its 200-day simple moving average is $5.06.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Biodexa Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, hitting $3.71. 36,695 shares of the company’s stock were exchanged, compared to its average volume of 1,241,775. Biodexa Pharmaceuticals has a fifty-two week low of $3.36 and a fifty-two week high of $74.00. The company has a 50 day moving average price of $4.29.